What Next for Vericel Corporation (VCEL) Stock After Today’s Big Increase?

March 14, 2018 - By Stephen Andrade

The stock of Vericel Corporation (NASDAQ:VCEL) is a huge mover today! The stock increased 2.64% or $0.3 during the last trading session, reaching $11.65. About 1.13 million shares traded or 15.95% up from the average. Vericel Corporation (NASDAQ:VCEL) has declined 10.47% since March 14, 2017 and is downtrending. It has underperformed by 27.17% the S&P500.
The move comes after 5 months positive chart setup for the $406.68 million company. It was reported on Mar, 14 by Barchart.com. We have $12.00 PT which if reached, will make NASDAQ:VCEL worth $12.20M more.

Vericel Corporation (NASDAQ:VCEL) Ratings Coverage

Among 4 analysts covering Vericel (NASDAQ:VCEL), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Vericel had 12 analyst reports since March 11, 2016 according to SRatingsIntel. The stock of Vericel Corporation (NASDAQ:VCEL) earned “Buy” rating by BTIG Research on Wednesday, August 9. The stock of Vericel Corporation (NASDAQ:VCEL) earned “Buy” rating by BTIG Research on Tuesday, November 7. The rating was upgraded by Needham on Friday, March 11 to “Buy”. The stock of Vericel Corporation (NASDAQ:VCEL) earned “Neutral” rating by Bank of America on Tuesday, April 5. The firm earned “Buy” rating on Tuesday, January 2 by Piper Jaffray. BTIG Research maintained the stock with “Buy” rating in Monday, March 5 report. On Thursday, December 22 the stock rating was initiated by Piper Jaffray with “Overweight”. The firm earned “Buy” rating on Wednesday, November 9 by Needham. The stock has “Buy” rating by Piper Jaffray on Wednesday, August 9. The stock of Vericel Corporation (NASDAQ:VCEL) earned “Buy” rating by Piper Jaffray on Tuesday, October 3.

More notable recent Vericel Corporation (NASDAQ:VCEL) news were published by: Globenewswire.com which released: “Vericel to Report Fourth-Quarter and Full-Year 2017 Financial Results on March …” on February 22, 2018, also Nasdaq.com with their article: “Vericel Corp. (VCEL) Has Climbed To A New High Following Q4 Report” published on March 05, 2018, Globenewswire.com published: “Vericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech …” on March 09, 2018. More interesting news about Vericel Corporation (NASDAQ:VCEL) were released by: Globenewswire.com and their article: “Vericel to Present at the 17th Annual Needham Healthcare Conference” published on March 13, 2018 as well as Prnewswire.com‘s news article titled: “Technical Perspectives on Biotech Stocks — Vericel, Viking Therapeutics …” with publication date: March 14, 2018.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, makes, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company has market cap of $406.68 million. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. It currently has negative earnings. The firm also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.